Bank of New York Mellon
NAVB

Bank of New York Mellon’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bank of New York Mellon’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,031
Closed -$19K – 4363
2019
Q1 		$19K Sell
7,031
-214
-3% -$631 ﹤0.01% 4168
2018
Q4 		$15K Hold
7,245
– – ﹤0.01% 4178
2018
Q3 		$33K Hold
7,245
– – ﹤0.01% 4172
2018
Q2 		$33K Sell
7,245
-2,843
-28% -$14.9K ﹤0.01% 4138
2018
Q1 		$72K Buy
10,088
+1,933
+24% +$14.5K ﹤0.01% 4111
2017
Q4 		$59K Buy
8,155
+910
+13% +$7.7K ﹤0.01% 4183
2017
Q3 		$60K Sell
7,245
-589
-8% -$4.99K ﹤0.01% 4082
2017
Q2 		$80K Buy
7,834
+59
+0.8% +$583 ﹤0.01% 4065
2017
Q1 		$90K Buy
7,775
+530
+7% +$6.02K ﹤0.01% 4052
2016
Q4 		$92K Sell
7,245
-538
-7% -$8.53K ﹤0.01% 4040
2016
Q3 		$142K Sell
7,783
-1,250
-14% -$15.8K ﹤0.01% 3969
2016
Q2 		$96K Sell
9,033
-20,345
-69% -$400K ﹤0.01% 4066
2016
Q1 		$555K Sell
29,378
-604
-2% -$11.6K ﹤0.01% 3391
2015
Q4 		$798K Buy
29,982
+150
+0.5% +$5.21K ﹤0.01% 3308
2015
Q3 		$1.36M Sell
29,832
-6,153
-17% -$232K ﹤0.01% 2994
2015
Q2 		$1.16M Buy
35,985
+2,242
+7% +$65.1K ﹤0.01% 3250
2015
Q1 		$1.07M Sell
33,743
-3,380
-9% -$114K ﹤0.01% 3266
2014
Q4 		$1.4M Sell
37,123
-1,242
-3% -$34.2K ﹤0.01% 3094
2014
Q3 		$1.01M Buy
38,365
+5,281
+16% +$140K ﹤0.01% 3277
2014
Q2 		$980K Buy
33,084
+2,590
+8% +$83.8K ﹤0.01% 3322
2014
Q1 		$1.13M Sell
30,494
-1,741
-5% -$66K ﹤0.01% 3209
2013
Q4 		$1.33M Sell
32,235
-32
-0.1% -$1.25K ﹤0.01% 3128
2013
Q3 		$1.71M Buy
32,267
+550
+2% +$32.1K ﹤0.01% 2937
2013
Q2 		$1.69M Buy
+31,717
New +$1.58M ﹤0.01% 2894

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon's NAVB Position: Q2 2019 in Review

Bank of New York Mellon sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 7,031 shares — an estimated $19K sold.

Bank of New York Mellon first reported a position in NAVB in Q2 2013 and held it in 24 quarters. The position peaked at $1.71M in Q3 2013. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

  • Bank of New York Mellon reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • Bank of New York Mellon sold 7,031 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $19K.
  • Bank of New York Mellon first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 24 quarters.
  • Bank of New York Mellon's Navidea Biopharmaceuticals Inc. position peaked at $1.71M in Q3 2013.
  • 27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Bank of New York Mellon's 13F filing for Q2 2019, filed 12 Aug 2019.